1 Reason I Wouldn’t Buy Centrica PLC Today

Royston Wild explains why nuclear problems at Centrica PLC (LON: CNA) should crimp group profits still further.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Today I am looking at why more upstream issues will dent Centrica’s (LSE: CNA) already-patchy earnings outlook.

Nuclear blowout hampers the bottom line

Centrica’s embattled upstream operations received a further blow last week when fellow energy giant EDF Energyannounced that it would be shuttering nuclear reactors at its Heysham 1 and Hartlepool power stations. Centrica owns a 20% stake in the French firm’s nuclear operations, so production problems here could have a sizeable impact on its own bottom line.

EDF Energy commented that a boiler spine defect had been discovered during standard inspections at Heysham 1in June, a scenario which ngthreatens a prolonged production blackout.

Indeed, the business advised that “until the results of the further inspections are known it is not possible to advise exact return to service dates for these four reactors,” and went on to comment that”an initial estimate is that these investigations will take around eight weeks”.

Centrica warned that this impact on its nuclear output is likely to harm earnings this year to the tune of 0.3p per share. But the question of when these investigations are likely to conclude — not to mention the extent of potential repair work as well as timing on when the plants will be back up to full capacity — could prompt a detrimental revision to these current earnings estimates.

The suspension also highlighted the creaking state of Britain’s nuclear fleet, and Centrica should not be surprised if similar problems spring up in the near future — its holding in EDF’s atomic energy business is spread across all eight of the French company’s UK nuclear stations.

Centrica’s nuclear exposure has been one of the few bright spots for its flailing upstream operations in recent times, and the impact of weak commodity prices drove operating profit at Centrica Energy more than a third lower to £526m during the 12 months ending June 2014. In this context a 2% uptick in operating profit from its nuclear sub-division, to £125m, can be viewed as a success, making last week’s news an even more bitter pill to swallow.

With Centrica also facing huge problems at its downstream operations through rising regulatory pressure and increased competition, this fresh problem adds another problem to the energy firm’s already-substantial list.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Royston Wild has no position in any shares mentioned. The Motley Fool has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

With £1,000 to invest, should I buy growth stocks or income shares?

Dividend shares are a great source of passive income, but how close to retirement, should investors think about shifting away…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett should buy this flagging FTSE 100 firm!

After giving $50bn to charity, Warren Buffett still has a $132bn fortune. Also, his company has $168bn to spend, so…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing For Beginners

I wish I’d known about this lucrative style of stock market investing 20 years ago

Research has shown that over the long term, this style of investing can generate returns in excess of those provided…

Read more »

Woman using laptop and working from home
Investing Articles

Is this growing UK fintech one of the best shares to buy now?

With revenues growing at 24% and income growing at 36%, Wise looks like one of the best shares to buy…

Read more »

Dividend Shares

Are Aviva shares one of the UK’s best investments today?

UK investors have been piling into Aviva shares recently. However, Edward Sheldon's wondering if he could get bigger returns elsewhere.

Read more »

Older couple walking in park
Investing Articles

10.2% dividend yield! 2 value shares to consider for a £1,530 passive income

Royston Wild explains why investing in these value shares could provide investors with significant passive income for years to come.

Read more »

man in shirt using computer and smiling while working in the office
Investing Articles

Nvidia and a FTSE 100 fund own a 10% stake in this $8 artificial intelligence (AI) stock

Ben McPoland explores Recursion Pharmaceuticals (NASDAQ:RXRX), an up-and-coming AI firm held by Cathie Wood, Nvidia and one FTSE 100 trust.

Read more »

Electric cars charging in station
Investing Articles

Is NIO stock poised for a great rebound?

NIO stock has risen 24.5% over the past month, coming off its lows following a solid month of vehicle deliveries.…

Read more »